EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Anti-TNFa therapy of rheumatoid arthritis: what have we learned?






Annual Review of Immunology 001: 3-96

Anti-TNFa therapy of rheumatoid arthritis: what have we learned?

Rheumatoid arthritis (RA), a systemic disease, is characterized by a chronic inflammatory reaction in the synovium of joints and is associated with degeneration of cartilage and erosion of juxta-articular bone. Many pro-inflammatory cytokines including TNFa, chemokines, and growth factors are expressed in diseased joints. The rationale that TNFa played a central role in regulating these molecules, and their pathophysiological potential, was initially provided by the demonstration that anti-TNFa antibodies added to in vitro cultures of a representative population of cells derived from diseased joints inhibited the spontaneous production of IL-1 and other pro-inflammatory cytokines. Systemic administration of anti-TNFa antibody or sTNFR fusion protein to mouse models of RA was shown to be anti-inflammatory and joint protective. Clinical investigations in which the activity of TNFa in RA patients was blocked with intravenously administered infliximab, a chimeric anti-TNFa monoclonal antibody (mAB), has provided evidence that TNF regulates IL-6, IL-8, MCP-1, and VEGF production, recruitment of immune and inflammatory cells into joints, angiogenesis, and reduction of blood levels of matrix metalloproteinases-1 and -3. Randomized, placebo-controlled, multi-center clinical trials of human TNFa inhibitors have demonstrated their consistent and remarkable efficacy in controlling signs and symptoms, with a favorable safety profile, in approximately two thirds of patients for up to 2 years, and their ability to retard joint damage. Infliximab (a mAB), and etanercept (a sTNF-R-Fc fusion protein) have been approved by regulatory authorities in the United States and Europe for treating RA, and they represent a significant new addition to available therapeutic options. Reprinted by permission of the publisher.


Accession: 009770095



Related references

Anonymous, 2007: Loss of expansion of CD94/NKG2a expressing T cells may predict disease relapse in patients with rheumatoid arthritis (RA) following withdrawal of anti-tumour necrosis factor-alpha(anti-TNFA) therapy

Feldmann, M.; Maini, R.N., 2001: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Rheumatoid arthritis (RA), a systemic disease, is characterized by a chronic inflammatory reaction in the synovium of joints and is associated with degeneration of cartilage and erosion of juxta-articular bone. Many pro-inflammatory cytokines incl...

Thirion, L.; Picard, D.; Mejjad, O.; Courville, P.; Le-Loet, X.; Joly, P., 2006: Necrotic ulcerations of cutaneous vasculitis in rheumatoid arthritis: treatment with anti-TNFa. Introduction. Anti-TNF alpha has occasionally been used in the treatment of recalcitrant forms of systemic vasculitis such as Behqet's disease, Wegener's granulomatosis and Churg-Strauss syndrome. We report on the outcome of treatment in...

Bazzichi, L.; Biasi, D.; Tinazzi, E.; Muratore, M.; Pellerito, R.; Russo, R.; Corsaro Santi, M.; D.S.ndre, P.; Epis, O.; Granata, M.; Kroegler, B.; Meschini, C.; Versace, F.; Astolfi, C.; Bombardieri, S.; Lunardi, C.; Adami, S.; Mathieu, A.; Pistone, G.; Sinigaglia, L.; Concesi, C.; Del Sante, G.; D.G.useppe, P.; Fusaro, E.; Laganà, B.; Malavolta, N.; Marasini, B.; Mazzone, A.; Romeo, N.; Leardini, G.; Martin Martin, L.Severino.; Migliore, A., 2016: Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study. The paper reports the results from the observational retrospective-prospective RUBINO study conducted in Italy to assess the safety of rituximab in the treatment of rheumatoid arthritis (RA) in routine clinical practice. The percentage of patients...

Lipsky, P.E.; van der Heijde, D.M.; S.C.air, E.W.; Furst, D.E.; Breedveld, F.C.; Kalden, J.R.; Smolen, J.S.; Weisman, M.; Emery, P.; Feldmann, M.; Harriman, G.R.; Maini, R.N., 2000: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Neutralization of tumor necrosis factor a (TNF-alpha) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not...

Alessandri, C.; Bombardieri, M.; Papa, N.; Cinquini, M.; Magrini, L.; Tincani, A.; Valesini, G., 2004: Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Objective: To investigate the effect of infliximab treatment on anti-cyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factor (RF) in patients with rheumatoid arthritis. Methods: 43 patients with rheumatoid arthritis not responding...

van Dartel, S.A.A.; Fransen, J.; Kievit, W.; Dutmer, E.A.J.; Brus, H.L.M.; Houtman, N.M.; van de Laar, M.A.F.; van Riel, P.L.C.M., 2013: Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. The use of TNF inhibitors leads to an increased risk of serious infections in RA. Predicting this risk would facilitate the prevention of serious infections. The objective of this study was to identify which factors are predictive of the increased...

Anonymous, 2012: What Have We Learned about the Pathogenesis of Rheumatoid Arthritis from TNF-Targeted Therapy?. Studies of cytokine regulation in rheumatoid arthritis led to the development of TNF? inhibitors which are now used for a number of indications, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, and ankylo...

Smolen, J.S.; Han, C.; Bala, M.; Maini, R.N.; Kalden, J.R.; van der Heijde, D.; Breedveld, F.C.; Furst, D.E.; Lipsky, P.E., 2005: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. To assess the relationship between inflammation and joint destruction in rheumatoid arthritis (RA) patients who have not responded clinically to treatment. Methods. Changes from baseline to week 54 in clinical variables and measures of radiographi...

Abdel-Nasser, A.M.; Mahmoud, M.H.; E.M.nsoury, T.M.; Osman, A.M., 2008: Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. To examine the diagnostic utility of the second generation of anti-cyclic citrullinated peptide (anti-CCP2) antibodies versus rheumatoid factor (RF) in rheumatoid arthritis (RA), and to study the association between anti-CCP2 and RA disease parame...